JPWO2020264512A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020264512A5
JPWO2020264512A5 JP2021577427A JP2021577427A JPWO2020264512A5 JP WO2020264512 A5 JPWO2020264512 A5 JP WO2020264512A5 JP 2021577427 A JP2021577427 A JP 2021577427A JP 2021577427 A JP2021577427 A JP 2021577427A JP WO2020264512 A5 JPWO2020264512 A5 JP WO2020264512A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538301A (ja
JP2022538301A5 (https=
JP7670632B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040164 external-priority patent/WO2020264512A1/en
Publication of JP2022538301A publication Critical patent/JP2022538301A/ja
Publication of JP2022538301A5 publication Critical patent/JP2022538301A5/ja
Publication of JPWO2020264512A5 publication Critical patent/JPWO2020264512A5/ja
Priority to JP2025017657A priority Critical patent/JP2025065311A/ja
Application granted granted Critical
Publication of JP7670632B2 publication Critical patent/JP7670632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577427A 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法 Active JP7670632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017657A JP2025065311A (ja) 2019-06-27 2025-02-05 Cns障害を治療するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962867695P 2019-06-27 2019-06-27
US201962867736P 2019-06-27 2019-06-27
US201962867734P 2019-06-27 2019-06-27
US62/867,695 2019-06-27
US62/867,734 2019-06-27
US62/867,736 2019-06-27
PCT/US2020/040164 WO2020264512A1 (en) 2019-06-27 2020-06-29 Compounds for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017657A Division JP2025065311A (ja) 2019-06-27 2025-02-05 Cns障害を治療するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022538301A JP2022538301A (ja) 2022-09-01
JP2022538301A5 JP2022538301A5 (https=) 2023-07-11
JPWO2020264512A5 true JPWO2020264512A5 (https=) 2023-07-11
JP7670632B2 JP7670632B2 (ja) 2025-04-30

Family

ID=71728948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577427A Active JP7670632B2 (ja) 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法
JP2025017657A Pending JP2025065311A (ja) 2019-06-27 2025-02-05 Cns障害を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017657A Pending JP2025065311A (ja) 2019-06-27 2025-02-05 Cns障害を治療するための組成物及び方法

Country Status (10)

Country Link
US (2) US20230257415A1 (https=)
EP (1) EP3990468A1 (https=)
JP (2) JP7670632B2 (https=)
CN (1) CN114729000A (https=)
AU (1) AU2020304679A1 (https=)
BR (1) BR112021026445A2 (https=)
CA (1) CA3143545A1 (https=)
MX (1) MX2021015854A (https=)
TW (1) TWI896548B (https=)
WO (1) WO2020264512A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN113166193B (zh) 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
IL283629B2 (en) 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CN116589521B (zh) * 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP7787635B2 (ja) 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) * 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
CN114656514B (zh) * 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
IL283629B2 (en) * 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them

Similar Documents

Publication Publication Date Title
JPWO2020264512A5 (https=)
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
JP4344235B2 (ja) タキソール増強剤化合物
US7402605B2 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
JP2021523221A5 (https=)
JP2020527175A5 (https=)
RU2011152891A (ru) Диарилгидантоины
JP2019512485A5 (https=)
CA2536136A1 (en) Aryloxy and arylalkyleneoxy substituted imidazoquinolines
RU2394028C2 (ru) Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
JPWO2020123827A5 (https=)
JP2023164918A5 (https=)
JPWO2020118060A5 (https=)
HRP20160652T1 (hr) Derivati oksazolina i izoksazolina kao crac modulatori
JPWO2020264509A5 (https=)
RU2007116987A (ru) Новые соединения
JPWO2021133896A5 (https=)
JPWO2020132504A5 (https=)
JPWO2019140272A5 (https=)
JP2021514399A5 (https=)
RU2017137366A (ru) Конденсированные бициклические соединения для лечения заболевания
JPWO2021003310A5 (https=)
JPWO2021188778A5 (https=)
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JPWO2020186006A5 (https=)